900.00% 0.018

Nkgen Biotech Inc (NKGN)

Panoramica Notizia Cronologia dei prezzi Perché NKGN Giù? Forum Previsione

Precedente Chiudi:

Volume 24 ore:

Relative Volume:

Capitalizzazione di mercato:

Utile/perdita netta:

Rapporto P/E:

Flusso di cassa netto:

1 W Prestazione:

1M Prestazione:

6M Prestazione:

1 anno Prestazione:

Intervallo 1D:

Intervallo di 1 settimana:

Portata 52W:

Nkgen Biotech Inc Stock (NKGN) Company Profile

Nkgen Biotech Inc

Healthcare (1146)

Biotechnology (639)

Prossima data di guadagno

Ultimi documenti SEC

NKGN's Discussions on Twitter

Confronta NKGN con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
NKGN Nkgen Biotech Inc	0.02	0	0	0	0	0.00
VRTX Vertex Pharmaceuticals Inc	412.22	104.45B	11.39B	3.64B	3.50B	13.99
ALNY Alnylam Pharmaceuticals Inc	469.36	60.95B	2.46B	-319.09M	-52.09M	-2.4669
REGN Regeneron Pharmaceuticals Inc	572.60	59.11B	14.21B	4.46B	3.56B	39.69
ARGX Argen X Se Adr	812.95	49.23B	3.06B	1.28B	447.35M	19.67
ONC Beone Medicines Ltd Adr	320.94	35.92B	4.56B	-176.77M	225.30M	-1.7177

Nkgen Biotech Inc Borsa (NKGN) Ultime notizie

Nkgen Biotech Inc Azioni (NKGN) Dati Finanziari

Non sono disponibili dati finanziari per Nkgen Biotech Inc (NKGN). Controlla altri titoli per ulteriori informazioni.

Nkgen Biotech Inc (NKGN)

Nkgen Biotech Inc Stock (NKGN) Company Profile

Confronta NKGN con altri titoli

Nkgen Biotech Inc Borsa (NKGN) Ultime notizie

NKGen Biotech provides clarification on quotation display, trading status - TipRanks

NKGen Biotech Provides Clarification on Quotation Display and Trading Status on the OTC Expert Market - The Manila Times

Form 10-K Filed Oct 8, 2025 — NKGen Biotech clarifies OTC Expert Market quotes; Common Stock remains tradable - Stock Titan

NKGen Biotech, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024 - MarketScreener

NKGen Biotech to Present on the Use of Troculeucel for - GlobeNewswire

NKGen Biotech to Present on the Use of Troculeucel for Neurodegenerative Diseases at the XXVII World Congress of Neurology - The Manila Times

NKGen to Present Troculeucel for Alzheimer's at WCN Oct 15 | NKGN Stock News - Stock Titan

NKGen Biotech (NYSE:NKGN) versus AlloVir (NASDAQ:ALVR) Critical Analysis - Defense World

NKGen Biotech Announces Consulting Agreement with Dr. Kim - MSN

NKGen Biotech Secures $2.5M in Stock Purchase Agreement - TipRanks

NKGen Biotech enters $2.5 million stock and warrant agreement with Asia Advisors - Investing.com Nigeria

NKGen Biotech enters $2.5 million stock and warrant agreement with Asia Advisors By Investing.com - Investing.com South Africa

NKGen Biotech CEO to present NK cell therapy data at China forum - Investing.com Australia

Breakthrough NK Cell Therapy for Neurodegenerative Diseases: NKGen Biotech Presents Latest Clinical Data - Stock Titan

LadRx (OTCMKTS:CYTR) & NKGen Biotech (NYSE:NKGN) Head-To-Head Analysis - Defense World

NKGen Biotech announces completion of NKMax acquisition - MSN

NKGen Biotech Acquires Majority Stake in NKMax - TipRanks

NKGen Biotech, Inc. Announces Completion of NKMax Co., Ltd. Acquisition; Gains Full Control of Global Manufacturing and Intellectual Property Assets - The Manila Times

NKGen Biotech, Inc. Announces Completion of NKMax Co., Ltd. - GlobeNewswire

$16.9M Strategic Acquisition: NKGen Biotech Gains Full Control of NK Cell Therapy Manufacturing & IP Portfolio - Stock Titan

Cell Dissociation Market Size Projected to Attain USD 1,451.89 Million by 2034 - GlobeNewswire

Alzheimer's Disease Pipeline 2025: Detailed Clinical Trials And FDA-Approved Therapies Review By Delveinsight Neurodon, Sangamo Therapeutics, Nkgen Biotech, Asceneuron, Truebinding, Alector - MenaFN

NKGen Biotech announces new funding to regain compliance with reporting obligations and listing standards - MSN

NKGen Biotech, Inc. (NYSE:NKGN) Short Interest Update - Defense World

NKGen Biotech To Present on Allogeneic Enhanced NK Cells - GlobeNewswire

Breakthrough: NKGen's NK Cell Cancer Therapy Eliminates Need for Harsh Pre-Treatment in Solid Tumors - Stock Titan

NKGen Biotech To Present on Allogeneic Enhanced NK Cells without Lymphodepletion in Solid Tumors at the 13th Annual Immuno-Oncology Summit - Yahoo Finance

Critical Contrast: NKGen Biotech (NYSE:NKGN) & Cortexyme (NASDAQ:CRTX) - Defense World

NKGen Biotech Presents Troculeucel Mechanism of Action with - GlobeNewswire

Revolutionary NK Cell Therapy Transforms Moderate Alzheimer's to Mild Stage in Clinical Trial - Stock Titan

NKGen Biotech to Present at the Alzheimer’s Association International Conference 2025 - GlobeNewswire

Revolutionary NK Cell Therapy Shows Promise in Alzheimer's Disease: Phase 1 Data Reveal Key Insights - Stock Titan

NKGen Biotech Gets FDA Expanded Access - Orange County Business Journal

NKGen Secures FDA Expanded Access For NK Cell Therapy In Neurodegenerative Diseases, Stock Down - Nasdaq

FDA grants expanded access for NKGen’s cell therapy in neurodegenerative diseases By Investing.com - Investing.com South Africa

FDA grants expanded access for NKGen’s cell therapy in neurodegenerative diseases - Investing.com Nigeria

NKGen Receives FDA Expanded Access Protocol Authorization for Landmark Treatment of Several Neurodegenerative Diseases - The Manila Times

NKGen Receives FDA Expanded Access Protocol Authorization - GlobeNewswire

FDA Grants Breakthrough Access: NKGen's NK Cell Therapy Now Available for Multiple Untreatable Brain Diseases - Stock Titan

NKGen Biotech and HekaBio enter strategic partnership to bring novel NK cell therapy to Japan - BioSpectrum Asia

NKGen Biotech and HekaBio Enter Strategic Partnership to Bring Novel NK Cell Therapy to Japan - The Manila Times

NKGen Biotech Partners with HekaBio for SNK01 in Japan - TipRanks

NKGen and HekaBio partner to advance NK cell therapy in Japan - Investing.com India

NKGen and HekaBio partner to advance NK cell therapy in Japan By Investing.com - Investing.com South Africa

Vivos Therapeutics shares rise 1.81% premarket after NKGen Biotech's new funding announcement. - AInvest

Revolutionary NK Cell Therapy Targets Alzheimer's: NKGen Secures Fast-Track Access to Japanese Market - Stock Titan

NKGen Biotech Announces New Funding to Regain Compliance with Reporting Obligations and Listing Standards - GlobeNewswire

NKGen Biotech (NYSE:NKGN) versus CEL-SCI (NYSE:CVM) Head-To-Head Comparison - Defense World

Nkgen Biotech Inc Azioni (NKGN) Dati Finanziari

Reddito

Reddito netto

Flusso di cassa

EPS

Simile a NKGN